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b-amyloid accumulation is a hallmark of Alzheimer’s disease pathology, but how does it cause
cognitive impairment? New findings described in this issue’s Select examine how b-amyloid
impacts signaling events at the synapse at early stages of disease progression. And at later stages,
one study suggests that Alzheimer’s patients exhibit a pronounced deficiency in their capacity to
metabolize b-amyloid.Cause and Eph-ect in Cognitive Dysfunction
Although oligomeric b-amyloid is often viewed as enemy number one in Alzheimer’s disease, it doesn’t act alone,
and unmasking its accomplicesmay point the way to new therapeutic strategies. An advance of this kind is made
by Cisse´ et al. (2011), whose work offers significant insight into how b-amyloid triggers pathological changes at
synapses. The authors examine trangenic mice overexpressing human amyloid precursor protein and provide
evidence that b-amyloid binds to the receptor tyrosine kinase EphB2. Binding promotes EphB2’s proteolytic
degradation, providing an explanation for previous reports that EphB2 is depleted early in the course of the
disease. Prior work has also shown that postsynaptic EphB2 regulates NMDA receptor trafficking and function.
In the current work, Cisse´ et al. show that restoring EphB2 expression in the granule cells of the dentate gyrus
ameliorates phenotypes associated with impaired NMDA receptor function, including the normalization of
long-term potentiation and impressive improvements on multiple cognitive tasks. What aspects of EphB2 func-
tion should be studied further by future investigators who have their eyes on potential therapeutics? For starters,
the interaction between EphB2 and oligomeric b-amyloid should be characterized in detail, here shown to involve
EphB2’s fibronectin domains. In addition, EphB2 is reported to directly interact with the NMDA receptor. Hence,
affecting this interaction could impact NMDA receptor surface expression. Additional targets to consider for
possible inolvement in pathways elicited by b-amyloid could include other known elements of EphB2 down-
stream signaling, including the kinase Src.
Cisse´ et al. (2011). Nature 469, 47–52.b-amyloid induces AMPA receptor
(AMPAr) dephosphorylation via a path-
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F. Cecconi.Caspase-3 Gets an Early Start
In Alzheimer’s disease, impaired performance on cognitive tasks precedes
the wholesale loss of neurons, suggesting that synaptic dysfunction is to
blame for early symptoms. Using a mouse model that expresses a mutant
allele of human amyloid precursor protein found in familial Alzheimer’s
disease (Tg2576 mice), D’Amelio et al. (2011) examine the onset of memory
decline and correlate its timing with molecular changes at the synapse. They
reveal that caspase-3 activation is elevated in the transgenic mice at the
onset of synaptic dysfunction in the hippocampus. Although the caspase-3
activation is above baseline, it is not high enough to trigger apoptosis and
is localized to the postsynaptic compartment. Caspase-3 activity is a known
activator of the protein phosphatase calcineurin, which in turn dephosphor-
ylates the AMPA receptor subunit GluR1 to regulate its subcellular distribu-
tion. Thus, in the current work, the authors provide evidence linking the
elevation in caspase-3 activity to a cascade of events that culminate in
a reduction in the level of AMPA receptors at postsynaptic densities. As
further evidence in support of the model and looking forward to future ther-
apeutic possibilities, the authors show that both the molecular and cognitive
phenotypes of Tg2576 mice are improved by the administration of caspase-3 inhibitors. A question left open
for future work is to establish what processes downstream of b-amyloid production contribute to elevated
caspase-3 activation.
D’Amelio et al. (2011). Nat. Neurosci. 14, 69–76.Cell 144, February 4, 2011 ª2011 Elsevier Inc. 315
Tauproteins do not normally go to
dendritic spines (red spines,
triangles) but are mislocalized
under disease conditions (yellow
spines, arrows). Image courtesy
of D. Liao.Where and When Does Tau Go Wrong?
Tau is a core component of neurofibrillary tangles, one of the hallmarks of Alz-
heimer’s disease and other dementias, but when and where does altered tau func-
tion have its detrimental effects? According to new findings by Hoover et al. (2010),
it is early, at synapses, and is independent of neurodegeneration. The authors
characterize mice expressing a human tau variant with a mutation associated
with frontotemporal dementia (rTgP301L mice) and show that mutant tau is mislo-
calized to dendritic spines in the first few months of life. This is noteworthy, as the
mislocalization occurs prior to the loss of synapses and neurons (which occur at
later stages in this mouse model) yet coincides with the onset of impairment in
cognitive tasks and synaptic plasticity. Probing the molecular basis for the
dysfunction, the authors link the mislocalization phenotype to a reduction in
AMPA and NMDA receptors in the postsynaptic membrane (see also the recent
work of Ittner et al. Cell 142, 387–397). They further show that the mislocalization
is dependent on tau phosphorylation. When 14 serines and threonines aremutated
to mimic hyperphosphorylation, tau is mistargeted to dendritic spines, and whenthe same residues are mutated to alanines to block phosphorylation, the mislocalization is alleviated. These find-
ings suggest that efforts to impede tau mislocalization at early stages of tauopathies might prevent some of their
most debilitating outcomes, thus raising the question: what molecular mechanisms make phosphorylated tau
prone to accumulation in dendritic spines?
Hoover et al. (2010). Neuron 68, 1067–1081.A theoretical graph shows the effects of increased
production (red) or decreased clearance (blue) as
possibilities for altered b-amyloid metabolism.
Image courtesy of R. Bateman.Work Slowdown by the b-Amyloid Clean-Up
Crew
Given that much of the emphasis in the Alzheimer’s research
community is placed on understanding the abberrant production of
toxic oligomeric species of b-amyloid, the recent report by Mawue-
nyaga et al. (2010) casts the molecular pathology of the disease in an
interesting and provocative light. By collecting cerebral spinal fluid
from individuals infused with 13C6-leucine to label newly synthesized
proteins, the authors probed the rates of production and clearance of
soluble b-amyloid. A comparison of control individuals and Alz-
heimer’s patients surprisingly reveals that the rates of production
of b-amyloid (both Ab40 and Ab42) are similar between the two
groups. Instead, stark differences are observed in their respective rates of b-amyloid clearance, with late-onset
Alzheimer’s patients exhibiting a 30% decrease. The authors calculate that this diminishment of b-amyloid
metabolism is consistent with a 10 year timeframe for the buildup of b-amyloid in the disease. An intriguing
question now is to determine what might account for the decreased capacity for soluble b-amyloid clearance
in Alzheimer’s patients. Also, how early in the disease process is altered b-amyloid metabolism a factor?
Does this point the way to new therapeutic approaches? If so, what existing soluble b-amyloid clean-up path-
ways in the central nervous systems might be ramped up to help counter its toxic accumulation?
Mawuenyega et al. (2010). Science 330, 1774.
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